ClinicalTrials.gg
RecruitingNCT05033028SOARUpdated Jun 23, 2026

Smartphones for Opiate Addiction Recovery

A Phase 3 interventional study of Smartphone app in Opioid-use Disorder, sponsored by NYU Langone Health. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by NYU Langone Health · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Opioid-Related Disorders by NYU Langone Health — 4 open to participants now, 5 under way, 1 of them phase 3. Opioid-Related Disorders · NYU Langone Health.

Planned enrollment
9th of 19
225 · median 217
Started
2021
with 2 others
Phase 3
2 of 23
1 open now
Registered
18th of 23
by date

Among the 23 studies in Opioid-Related Disorders by NYU Langone Health, this one is the 9th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2021, is one of 2 in phase 3, and was the 18th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 23 studies in Opioid-Related Disorders by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Opioid-Related Disorders by NYU Langone Health, or all of them as a file.
02

Study summary

Treatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use during treatment has thus recently become a major NIDA policy goal. The 5-minute battery indicates the numerical probability that a patient will reuse illicit opiates within the next 7-10 days.

Read the detailed description

The primary goal in this mid-scale clinical trial is to test the hypothesis that clinicians who use the output of the mobile system to adjust buprenorphine and methadone dosing achieve lower opiate reuse rates than physicians who provide care-as-usual. The secondary goal is to examine the usability and desirability of this solution for clinicians with an eye to usability and large-scale deployment. The third and final goal is to measure the cost-effectiveness of this solution from multiple perspectives. If successful it will be possible to employ an algorithmic and measurement-based approach to OUD treatment with methadone and buprenorphine which reduces reuse rates and relapse rates amongst OUD patients.

03

Conditions studied

  • Opioid-use Disorder
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients:

  • Meet criteria for opioid-use disorder (heroin and/or prescription opioids);
  • Have entered, or expressed a clear intention to enter, an OUD treatment program that prescribes either methadone or buprenorphine
  • Any gender;
  • 18 years of age and older;
  • Have used opioids other than as specifically prescribed within thirty days prior to consent;
  • In good-enough general health;
  • Capacity to provide written as assessed by our Subject Comprehension Assessment Tool(subjects lacking the ability to consent will not be enrolled) ;
  • Able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study.

Study-Physician Participants.

  • Licensed MD employed by the respective site, or at a clinical partner of the respective site, where they will act as participants and be part of the treatment team
  • Currently practicing in the treatment of OUD with either Buprenorphine or Methadone;
  • Able to speak, read, and write English fluently and to provide informed consent in English

Clinician Participants.

  • Licensed MSW, NP, or MD; who are not part of any treatment team within the study and may be employees of their respective sites or other treatment facilities.
  • Currently practicing in the treatment of OUD with either Buprenorphine or Methadone;
  • Able to speak, read, and write English fluently and to provide informed consent in English

Exclusion criteria

Exclusion Criteria:

Patients:

  • Serious medical, psychiatric or non-opioid substance use disorder that, in the opinion of a study physician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include: (a) Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
  • Severe, untreated or inadequately treated mental disorder (e.g., active psychosis, uncontrolled manic-depressive illness) as assessed by history and/or clinical interview;
  • Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use likely to require a complicated medical detoxification (routine alcohol and sedative detoxifications may be included);
  • Suicidal or homicidal ideation that requires immediate attention;
  • Presence of pain of sufficient severity as to require ongoing pain management with opioids;
  • Pending legal action or other reasons that might prevent an individual from completing the study.
  • Pregnancy as assessed by urine pregnancy testing
  • Breastfeeding of infants, as assessed by self-report.
  • Prisoners, as defined by OHRP, are excluded from participation in the study.
  • Individuals receiving residential court-ordered substance abuse treatment.

Study-Physician Participants.

  • none

Clinician Participants.

  • none
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
225 participants (estimated)

Study arms

  • No intervention
    Treatment-as-Usual

    Participants will receive the same treatment as if they had not joined the study

  • Experimental
    Smartphone with dose changes after using

    Participants will have an app installed on their phone and have to complete a brief questionnaire and some days play a 2-4 minute game.

    Other: Smartphone app

  • Experimental
    Smartphone with dose changes before using

    Participants will have an app installed on their phone and have to complete a brief questionnaire and some days to play a 2-4 minute game.

    Other: Smartphone app

  • Experimental
    Focus group with Study Physicans

    Study physicians asked to participate in a focus group session or 1:1 interviews if unable to attend the focus group during year one of the study and once annually towards the end of years 2, 3, 4, and 5 of the study

    Other: Smartphone app

  • Experimental
    Focus group with Clinicians

    Clinicians asked to participate in a 1:1 interview and a separate focus group at roughly the same time. Prior to the first structured interview with our study team, you will participate in a 1-hour training and familiarization session with the SOAR system using synthetic or training data.

    Other: Smartphone app

Interventions

  • OtherSmartphone app

    SOAR (Smartphones for Opioid Addiction Recovery) system (battery + platform) as a tool for adjusting MOUD dosages to reduce treatment dropout.

06

What researchers measure

Primary outcomes

  1. Proportion of patients will reduce illicit substance reuse rates with PREDICTIVE-DOSING relative to treatment as usual (TAU).

    This is measured by collecting one salivary drug test every two weeks in addition to any drug testing they may complete as part of their clinical treatment. Once saliva samples are obtained they will be aggregated and sent weekly for analysis by mass spectrometry. The primary outcome from these data will be the number of toxicology tests positive for illicit opioids. These data are count in nature and truncated at both 0 and 12.

    Time frame: 1 month visit, 3 months visit, 6 months visit

Secondary outcomes

  1. To assess the impact of POSTUSE-DOSING on reuse rates relative to TAU

    This will be measured through self reports through the smartphone and assessed by randomly scheduled, remote drug screens with saliva samples.

    Time frame: 1 month visit, 3 months visit, 6 months visit

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: Researchers who provide a methodologically sound proposal. Upon reasonable request. Requests should be directed to Paul.glimcher@nyulangone.org To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Jun 2027, 67 months after the start.

Of 31 phase 3 interventional studies under Opioid-Related Disorders, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2021
First posted
Sep 2, 2021
StartActual
Nov 1, 2021
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05033028
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Nov 1, 2021
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jun 23, 2026

Study contacts

Paul Glimcher
Contact
Paul.glimcher@nyulangone.org
212-263-8167
Stephen Ross, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion